Septerna (SEPN) Non Operating Income (2023 - 2026)
Septerna (SEPN) posted quarterly Non Operating Income of $5.0 million for Q1 2026, up 12.76% year-over-year from $4.4 million in Q1 2025, and down 5.61% quarter-over-quarter from $5.3 million in Q4 2025.
Septerna (SEPN) Non Operating Income (2023 - 2026) Analysis & Trends
Septerna's Non Operating Income history runs 4 years deep, the most recent figure standing at $5.0 million for Q1 2026.
- In Q1 2026, Non Operating Income rose 12.76% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $20.0 million (up 70.47% YoY), while the FY2025 annual figure was $19.4 million, up 127.86% from the prior year.
- Non Operating Income for Q1 2026 stood at $5.0 million, down from $5.3 million in the prior quarter.
- The five-year high for Non Operating Income was $5.6 million in Q3 2025, with the low at $1.1 million in Q3 2023.
- The 4-year median for Non Operating Income is $3.9 million (2024), against an average of $3.2 million.
- The sharpest annual moves came in 2025 and 2026: Non Operating Income surged 260.19% in 2025, then increased 12.76% in 2026.
- Septerna's Non Operating Income stood at $1.3 million in 2023, then jumped by 206.78% to $3.9 million in 2024, then surged by 36.17% to $5.3 million in 2025, then dropped by 5.61% to $5.0 million in 2026.
- Business Quant data shows SEPN's Non Operating Income at $5.0 million in Q1 2026, $5.3 million in Q4 2025, and $5.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Septerna | 2.08 Bn | 2.08 Bn | - | 4.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.78 Mn |
| Mar 31, 2026 | 5.00 Mn |
| Dec 31, 2025 | 5.30 Mn |
| Sep 30, 2025 | 5.56 Mn |
| Jun 30, 2025 | 4.14 Mn |
| Mar 31, 2025 | 4.43 Mn |
| Dec 31, 2024 | 3.89 Mn |
| Sep 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 1.52 Mn |
| Mar 31, 2024 | 1.23 Mn |
| Dec 31, 2023 | 1.27 Mn |
| Sep 30, 2023 | 1.10 Mn |